Table 1.
Antibody therapeutics approved in the European Union or United States during 2017*.
| International non-proprietary name | Brand name | Target; Format | Indication first approved | Date of first EU approval | Date of first US approval |
|---|---|---|---|---|---|
| Brodalumab | Siliq, Lumicef, Kyntheum | IL-17RA; Human IgG2 | Plaque psoriasis | 7/17/17 | 2/15/17 |
| Avelumab | Bavencio | PD-L1; Human IgG1 | Merkel cell carcinoma | 9/18/17 | 3/23/17 |
| Dupilumab | Dupixent | IL-4Rα; Human IgG4 | Atopic dermatitis | 9/27/17 | 3/28/17 |
| Ocrelizumab | Ocrevus | CD20; Humanized IgG1 | Multiple sclerosis | EC decision pending | 3/29/17 |
| Durvalumab | Imfinzi | PD-L1; Human IgG1 | Bladder cancer | In review | 5/1/17 |
| Sarilumab | Kevzara | IL-6R; Human IgG1 | Rheumatoid arthritis | 6/23/17 | 5/22/17 |
| Guselkumab | Tremfya | IL-23 p19; Human IgG1 | Plaque psoriasis | 11/23/17 | 7/13/17 |
| Inotuzumab ozogamicin | Besponsa | CD22; Humanized IgG4; ADC | Acute lymphoblastic leukemia | 6/29/17 | 8/17/17 |
| Benralizumab | Fasenra | IL-5R α; Humanized IgG1 | Asthma | EC decision pending | 11/14/17 |
| Emicizumab | Hemlibra | Factor IXa, X; Humanized IgG4, bispecific | Hemophilia A | In review | 11/16/17 |
Table notes: Sarilumab's first global approval was granted in Canada on January 12, 2017; brodalumab's first global approval was granted in Japan on July 4, 2016. *Data available as of December 1, 2017
Abbreviations: ADC, antibody drug conjugate; CD, cluster of differentiation; EC, European Commission; EU, European Union; IL, interleukin; IgG, immunoglobulin G; PD-L1, programmed cell death 1.